166 related articles for article (PubMed ID: 34327425)
21. Impact of investigator initiated trials and industry sponsored trials on medical practice (IMPACT): rationale and study design.
Nury E; Bischoff K; Wollmann K; Nitschke K; Lohner S; Schumacher M; Rücker G; Blümle A
BMC Med Res Methodol; 2020 Oct; 20(1):246. PubMed ID: 33008297
[TBL] [Abstract][Full Text] [Related]
22. Trends in Molecular Testing of Lung Cancer in Mainland People's Republic of China Over the Decade 2010 to 2019.
Li W; Lyu Y; Wang S; Zhou X; Ma J; Xu C; Fang L; Ying J;
JTO Clin Res Rep; 2021 Apr; 2(4):100163. PubMed ID: 34590013
[TBL] [Abstract][Full Text] [Related]
23. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020.
Wu X; Zhang F; Yu M; Wang H
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):903-909. PubMed ID: 35711154
[TBL] [Abstract][Full Text] [Related]
24. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.
Huang H; Tang Y; Wu D; Meng X; Wang S; Wang J; Yu Y; Fang Y; Fang H; Zhu Q; Li N; Xu B; Sun Y; He J
BMC Geriatr; 2023 Mar; 23(1):199. PubMed ID: 36997858
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021.
Hao J; Li C; Li J; Wang C; Li Y; He C; Liu W; Li S; Zuo L; Hui W
Am J Cardiovasc Drugs; 2023 May; 23(3):301-310. PubMed ID: 36917444
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and trends of clinical studies primarily sponsored by China in WHO primary registries between 2009 and 2018: a cross-sectional survey.
Xu Y; Dong M; Liu X
BMJ Open; 2020 Nov; 10(11):e037262. PubMed ID: 33444176
[TBL] [Abstract][Full Text] [Related]
27. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility.
Zhuang M; Zhao S; Jiang Z; Wang S; Sun P; Quan J; Yan D; Wang X
EBioMedicine; 2019 Mar; 41():286-298. PubMed ID: 30797712
[TBL] [Abstract][Full Text] [Related]
28. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
29. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
30. Chinese villages and their sustainable future: the European Union-China-Research Project "SUCCESS".
Dumreicher H
J Environ Manage; 2008 Apr; 87(2):204-15. PubMed ID: 17888563
[TBL] [Abstract][Full Text] [Related]
31. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.
Chen K; Jiang K; Tang L; Chen X; Hu J; Sun F
Front Oncol; 2021; 11():647110. PubMed ID: 34084744
[TBL] [Abstract][Full Text] [Related]
34. Trends in innovative pediatric drug development in China based on clinical trial registration data.
Wu WW; Ji X; Mou XS; Ma XY; Huang YT; Zhang JY; Zhang JX; Xie XR; Mao NY; Xu J
Front Med (Lausanne); 2023; 10():1187547. PubMed ID: 37484857
[TBL] [Abstract][Full Text] [Related]
35. General characteristics and reasons for the discontinuation of drug clinical trials in mainland China.
Huo BN; Ai ML; Jia YT; Liu Y; Wang Y; Yin NG; Song L
BMC Med Res Methodol; 2021 Nov; 21(1):246. PubMed ID: 34773983
[TBL] [Abstract][Full Text] [Related]
36. Assisted reproductive technology service availability, efficacy and safety in mainland China: 2016.
Bai F; Wang DY; Fan YJ; Qiu J; Wang L; Dai Y; Song L
Hum Reprod; 2020 Feb; 35(2):446-452. PubMed ID: 32020190
[TBL] [Abstract][Full Text] [Related]
37. [Features of Clinical Register of Chinese Medicine and Pharmacy Based on ClinicalTrials.gov. (USA)].
Lu PF; Liao X; Xie YM; Wang ZG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Nov; 35(11):1388-92. PubMed ID: 26775492
[TBL] [Abstract][Full Text] [Related]
38. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
Wu JT; Leung K; Leung GM
Lancet; 2020 Feb; 395(10225):689-697. PubMed ID: 32014114
[TBL] [Abstract][Full Text] [Related]
39. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
40. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
